Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease

References

• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.
   PubMed Web of Science ®Google Scholar
• Tumati V, Iyengar P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 21):S2537–S2544.
   PubMed Web of Science ®Google Scholar
• Patel PH, Palma D, McDonald F, et al. The Dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol). 2019;31(12):824–833.
   PubMed Web of Science ®Google Scholar
• Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016;89(1066):20160251.
   PubMed Web of Science ®Google Scholar
• Kim C, Hoang CD, Kesarwala AH, et al. Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol. 2017;12(2):179–193.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing (vol 366, pg 883, 2012). N Engl J Med, 2012;367(10):976–976.
   Web of Science ®Google Scholar
• Soucheray M, Capelletti M, Pulido I, et al. Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition. Cancer Res. 2015;75(20):4372–4383.
   PubMed Web of Science ®Google Scholar
• Campo M, Al-Halabi H, Khandekar M, et al. Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. Oncologist. 2016;21(8):964–973.
   PubMed Web of Science ®Google Scholar
• Kelly P, Ma Z, Baidas S, et al. Patterns of progression in metastatic estrogen receptor positive breast cancer: an argument for local therapy. Int J Breast Cancer. 2017;2017:1367159.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat ST, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Franceschini D, De Rose F, Cozzi S, et al. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non-small cell lung cancer: state of the art. Crit Rev Oncol Hematol. 2020;148:102894.
   PubMed Web of Science ®Google Scholar
• Lara TM, Helou J, Poon I, et al. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy? Lung Cancer. 2018;124:219–226.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13(5):515–524.
   PubMed Web of Science ®Google Scholar
• Gridelli C, De Marinis F, Cappuzzo F, et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014;15(3):173–181.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–1814.
   PubMed Web of Science ®Google Scholar
• Triggiani L, Alongi F, Buglione M, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116(12):1520–1525.
   PubMed Web of Science ®Google Scholar
• Santini D, Ratta R, Pantano F, et al. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. Oncotarget. 2017;8(59):100708–100716.
   PubMedGoogle Scholar
• Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37(8):4078–4101.
   PubMed Web of Science ®Google Scholar
• Sahgal A, Roberge D, Schellenberg D, et al. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R Coll Radiol). 2012;24(9):629–639.
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346.
   PubMed Web of Science ®Google Scholar
• Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35(4):627–634.
   PubMed Web of Science ®Google Scholar
• Saravana-Bawan B, Bajwa A, Paterson J, et al. Active surveillance of low-risk papillary thyroid cancer: a meta-analysis. Surgery. 2020;167(1):46–55.
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu H, Meng S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10(2):522–529.
   PubMed Web of Science ®Google Scholar
• Borghetti P, Bonù ML, Giubbolini R, et al. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med. 2019;124(7):662–670.
   PubMed Web of Science ®Google Scholar
• Triggiani L, Mazzola R, Magrini SM, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37(12):2631–2637.
   PubMed Web of Science ®Google Scholar
• Pembroke CA, Fortin B, Kopek N. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. Radiother Oncol. 2018;127(3):493–500.
   PubMed Web of Science ®Google Scholar
• Cheung P, Patel SI, North S, et al. Stereotactic radiotherapy for oligoprogression in metastatic kidney cancer patients receiving tyrosine kinase inhibitor therapy: a prospective phase II multi-centre study. Int J Radiat Oncol Biol Phys. 2020;108(3):S27–S28.
   PubMed Web of Science ®Google Scholar
• Gan GN, Weickhardt AJ, Scheier B, et al. Stereotactic radiation therapy can safely and durably control sites of extra-Central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–898.
   PubMed Web of Science ®Google Scholar
• Ingrosso G, Detti B, Fodor A, et al. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol. 2021;23(8):1577–1578.
   PubMed Web of Science ®Google Scholar
• Ji X, Zhao Y, Zhu X, et al. Outcomes of stereotactic body radiotherapy for metastatic colorectal cancer with oligometastases, oligoprogression, or local control of dominant tumors. Front Oncol. 2021;10:3265.
   Web of Science ®Google Scholar
• Meyer E, Pasquier D, Bernadou G, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer. 2018;98:38–47.
   PubMed Web of Science ®Google Scholar